<DOC>
	<DOC>NCT00984126</DOC>
	<brief_summary>This trial is conducted in Asia, Europe, Japan, Oceania, North America and South America. The aim of the trial is to investigate the safety and efficacy of turoctocog alfa (N8) in Haemophilia A patients. The trial is an extension to trials NN7008-3543 (start: March 2009, stop: September 2011) and NN7008-3545 (start: May 2010, stop: November 2011) and the pharmacokinetic trials NN7008-3600 (start: November 2010, stop: October 2011), NN7008-3893 (start: June 2011, stop: September 2011) and NN7008-4015 (start: August 2012, stop: March 2013).</brief_summary>
	<brief_title>Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed Consent obtained before any trialrelated activities Completion of trial NN70083543 or paediatric trial NN70083545 or Japanese trial NN70083600 or pharmacokinetic trial NN70083893 or NN70084015 Previous participation in the current trial (defined as withdrawal) or withdrawn subjects from NN70083522, NN70083543, NN70083545, NN70083600, NN70083893 or NN70084015 after administration of trial product</criteria>
	<gender>Male</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>